Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer.

Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head... The overall survival of patients with squamous cell cancer of the head and neck has not significantly improved over the past 2 decades. Preclinical studies suggest that combining a monoclonal antibody to the epidermal growth factor receptor with irradiation or chemotherapy agents active in squamous cell cancer of the head and neck could increase treatment efficacy. Completed phase I studies have shown these combinations to be both feasible and tolerable. Phase III studies are now beginning to establish firmly the efficacy of this innovative new approach. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current opinion in oncology Pubmed

Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer.

Current opinion in oncology , Volume 11 (3): 4 – Jun 28, 1999

Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer.


Abstract

The overall survival of patients with squamous cell cancer of the head and neck has not significantly improved over the past 2 decades. Preclinical studies suggest that combining a monoclonal antibody to the epidermal growth factor receptor with irradiation or chemotherapy agents active in squamous cell cancer of the head and neck could increase treatment efficacy. Completed phase I studies have shown these combinations to be both feasible and tolerable. Phase III studies are now beginning to establish firmly the efficacy of this innovative new approach.

Loading next page...
 
/lp/pubmed/monoclonal-antibodies-as-potentiators-of-radiotherapy-and-chemotherapy-Y408ZW8VjF

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1040-8746
DOI
10.1097/00001622-199905000-00009
pmid
10328593

Abstract

The overall survival of patients with squamous cell cancer of the head and neck has not significantly improved over the past 2 decades. Preclinical studies suggest that combining a monoclonal antibody to the epidermal growth factor receptor with irradiation or chemotherapy agents active in squamous cell cancer of the head and neck could increase treatment efficacy. Completed phase I studies have shown these combinations to be both feasible and tolerable. Phase III studies are now beginning to establish firmly the efficacy of this innovative new approach.

Journal

Current opinion in oncologyPubmed

Published: Jun 28, 1999

There are no references for this article.